JNJ

Top 10 pharma R&D budgets in 2022
Top 10 pharma R&D budgets in 2022
Fierce Biotech
R&D
Roche
JNJ
Merck
Pfizer
Novartis
AstraZeneca
Bristol Myers Squibb
Eli Lilly
Sanofi
AbbVie
Flag link:
Lazertinib and Tagrisso go head to head
Lazertinib and Tagrisso go head to head
EP Vantage
AstraZeneca
lazertinib
Tagrisso
JNJ
lung cancer
Flag link:
After appeals loss, Johnson & Johnson will take Texas two-step case to the US Supreme Court
After appeals loss, Johnson & Johnson will take Texas two-step case to the US Supreme Court
Fierce Pharma
JNJ
legal
Supreme Court
bankruptcy
Flag link:
J&J finalizes $25M settlement, laying Remicade antitrust allegations to rest
J&J finalizes $25M settlement, laying Remicade antitrust allegations to rest
Endpoints
JNJ
legal
Remicade
antitrust
biosimilars
Flag link:
Most-clicked pharma news for week ending March 18 2023: Medtronic offers early retirement package, Novartis to sell ophthalmological assets, and Pfizer tops list of drugs with price increases
Most-clicked pharma news for week ending March 18 2023: Medtronic offers early retirement package, Novartis to sell ophthalmological assets, and Pfizer tops list of drugs with price increases
CP WIre
Medtronic
Medtech
inflation
drug pricing
Pfizer
Novartis
Merck
Bristol Myers Squibb
Keytruda
Opdivo
Yervoy
lung cancer
Xiidra
JNJ
executive compensation
Flag link:
Most-clicked pharma news for week ending March 18 2023: Medtronic offers early retirement package, Novartis to sell ophthalmological assets, and Pfizer tops list of drugs with price increases
Medtronic
Medtech
inflation
drug pricing
Pfizer
Novartis
Merck
Bristol Myers Squibb
Keytruda
Opdivo
Yervoy
lung cancer
Xiidra
JNJ
executive compensation
Flag link:
Johnson & Johnson shelves Carvykti's UK launch amid manufacturing shortfalls
Johnson & Johnson shelves Carvykti's UK launch amid manufacturing shortfalls
Fierce Pharma
JNJ
Legend Biotech
CAR-T
Carvykti
Flag link:
In his first year as Johnson & Johnson CEO, Duato scored $13.1M payout
In his first year as Johnson & Johnson CEO, Duato scored $13.1M payout
Fierce Pharma
Joaquin Duato
JNJ
Pharma CEOs
executive compensation
Flag link:
J&J lays off 350 people at robotics units, says ‘we have to get better’ with Ottava
J&J lays off 350 people at robotics units, says ‘we have to get better’ with Ottava
Medtech Dive
JNJ
layoffs
robotic surgery
Auris Health
Verb Surgical
Ottava
Flag link:
Johnson & Johnson is cutting jobs in its MedTech business
Johnson & Johnson is cutting jobs in its MedTech business
Mass Device
JNJ
layoffs
Medtech
Flag link:
J&J-backed startup launches with $100M to build better brain drugs
J&J-backed startup launches with $100M to build better brain drugs
BioPharma Dive
Rapport Therapeutics
JNJ
Neuroscience
neurological disorders
Flag link:
ACC23: J&J's combo pill of Opsumit plus tadalafil improves blood flow in PAH patients
ACC23: J&J's combo pill of Opsumit plus tadalafil improves blood flow in PAH patients
Fierce Pharma
JNJ
ACC
Opsumit
Opsynvi
Flag link:
Citing J&J's 'failure to comply' with court rules, judge nixes early bid to block Amgen's Stelara biosim
Citing J&J's 'failure to comply' with court rules, judge nixes early bid to block Amgen's Stelara biosim
Fierce Pharma
JNJ
patents
Janssen
Amgen
biosimilars
Stelara
Flag link:
Spotlight – What is next in Nash
Spotlight – What is next in Nash
EP Vantage
NASH
clinical trials
89Bio
Arrowhead Pharmaceuticals
Can-Fite BioPharma
Ewopharma
Hepagene Therapeutics
JNJ
Ligand Pharmaceuticals
Madrigal Pharmaceuticals
Merck
NGM Biopharmaceuticals
NorthSea Therapeutics
Novartis
Sagimet Biosciences
Terns Pharmaceuticals
Viking Therapeutics
Flag link:
Bristol Myers, J&J plan tests of new blood thinner in nearly 50,000 patients
Bristol Myers, J&J plan tests of new blood thinner in nearly 50,000 patients
BioPharma Dive
Bristol Myers Squibb
JNJ
clinical trials
Librexia
bloodthinners
Flag link:
Big-sellers from Merck, Novo and Lilly likely to face Medicare price negotiations: report
Big-sellers from Merck, Novo and Lilly likely to face Medicare price negotiations: report
Fierce Pharma
Medicare
drug pricing
Merck
Novo Nordisk
Eli Lilly
Boehringer Ingelheim
JNJ
Flag link:
After spending $6.5B for Momenta, J&J readies 'pipeline in a product' for pivotal year
After spending $6.5B for Momenta, J&J readies 'pipeline in a product' for pivotal year
Fierce Biotech
JNJ
Janssen
nipocalimab
Momenta Pharmaceuticals
Flag link:
J&J wins EU backing for PARP combo Akeega in prostate cancer—but only in some patients
J&J wins EU backing for PARP combo Akeega in prostate cancer—but only in some patients
Fierce Pharma
JNJ
Akeega
prostate cancer
PARP inhibitors
Flag link:
J&J to impose new limits on 340B access after industry court win
J&J to impose new limits on 340B access after industry court win
Endpoints
JNJ
340B
legal
Flag link:
Gilead, Teva and J&J's HIV antitrust case inches closer to trial as judge keeps most claims on the table
Gilead, Teva and J&J's HIV antitrust case inches closer to trial as judge keeps most claims on the table
Fierce Pharma
Gilead Sciences
legal
HIV
antitrust
Teva Pharmaceutical
JNJ
Flag link:

Pages